• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Risperdal (risperidone)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2009

  • Risperdal (risperidone) 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg tablets
  • Risperdal (risperidone) 1 mg / mL oral solution 
  • Risperdal CONSTA (risperidone) 12.5 mg / vial, 25 mg / vial, 37.5 mg / vial, and 50 mg / vial Long-Acting injection 
  • Risperdal M-TAB (risperidone) 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg Orally Disintegrating tablets

 

Summary View

 

PRECAUTIONS

Leukopenia, Neutropenia and Agranulocytosis
  • Class Effect: In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including Risperdal. Agranulocytosis has also been reported.
  • Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of Risperdal should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.
  • Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm3) should discontinue Risperdal and have their WBC followed until recovery.